Each 1 ml Contains:
Metronidazole 125 mg
Metronidazole is an anti-protozoal drug from nitroimidazole derivative, after Metronidazole has penetrated the bacteria the molecule is reduced by the sensitive bacteria (anaerobe). The metabolites that are created have a toxic effect on the bacteria through binding to the bacterial DNA. In general metronidazole is bactericidal for sensitive bacteria in concentrations equal to or little higher than the min after metronidazole has penetrated the bacteria the molecule is reduced by the sensitive bacteria (anaerobe). The metabolites that are created have a toxic effect on the bacteria through binding to the bacterial DNA. In general metronidazole is bactericidal for sensitive bacteria in concentrations equal to or a little higher than the minimum inhibiting concentration (MIC). Clinically metronidazole does not have any relevant effect on facultative anaerobe, obligate aerobe and microaerophilic bacteria. Metronidazole is also active in protozoa. In Giardia spp. in particular, metronidazole primarily argets the trophozoites (active replication of the parasite) tresulting in their death and by consequence leading to dramatic decrease in cyst shedding.
.
– Treatment of infections of the gastrointestinal tract caused by Giardia spp. and Clostridium spp. (i.e. C. perfringens or C. difficile).
-Treatment of infections of the urogenital tract, oral cavity, throat and skin caused by obligate anaerobic bacteria (e.g. Clostridium spp.) susceptible to metronidazole.
Dogs
For whole Product : 0.4 mL of Product / kg bodyweight, preferably given in two equally divided doses ( 0.2 mL of Product / kg bodyweight twice daily) for 5-7 days.
For doses requiring more than two filled syringes, the dosing should be twice daily in order to minimize counting and dosing errors.
-Do not use in case of hepatic disorders.
-Do not use in case of hypersensitivity to the active substance or to any of the excipients.
The following adverse reactions may occur after administration of metronidazole: vomiting, hepatotoxicity and neutropenia. In very rare cases, neurological signs may occur especially after prolonged treatment with metronidazole
– Adverse events are more likely to occur at doses and treatment durations in excess of the recommended treatment regimen.
– If neurological signs occur, treatment should be discontinued and the patient should be treated symptomatically.
Not applicable
Store at temperature not exceeding 30ºc.
Opaque white (HDPE) plastic bottle contains 20,25,50,75,100, 200, 250, 750, 1000 ml of oral solution Lined with red (HDPE) plastic film with aluminum seal closed by white (HDPE) plastic cap with (LDPE) inner foam liner with an outer label without insert